Filament will license PEX010, its proprietary botanical psilocybin drug candidate, to Cybin Therapeutics for use in two upcoming Phase II clinical trials awaiting Health Canada approval VANCOUVER, BC, Jan. 14, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it…


Previous articlePsychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule Psilocybin Emerges; We Review Psychedelic Research and Trials from 2021
Next articlePsychedelic Research Bulletin: December 2021